Stockscreener 앱 받기
8.27
2.25%
-0.19
전일 마감가:
$8.46
열려 있는:
$8.51
하루 거래량:
173.57K
Relative Volume:
0.56
시가총액:
$662.53M
수익:
-
순이익/손실:
$-83.12M
주가수익비율:
-5.5292
EPS:
-1.4957
순현금흐름:
$-114.50M
1주 성능:
-6.02%
1개월 성능:
-7.18%
6개월 성능:
-33.31%
1년 성능:
+0.00%
1일 변동 폭
$8.1489
$8.665
1주일 범위
$8.00
$9.00
52주 변동 폭
$8.00
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
명칭
Bridgebio Oncology Therapeutics Inc
전화
857 702 0377
주소
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
8.27 | 662.53M | 0 | -83.12M | -114.50M | -1.4957 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-11 | 개시 | Stifel | Buy |
| 2026-01-09 | 개시 | Raymond James | Outperform |
| 2025-12-05 | 개시 | Morgan Stanley | Overweight |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Piper Sandler | Overweight |
모두보기
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
[EFFECT] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price Today & Analysis - Gotrade
BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT) - Stock Titan
Ex-CEO Wallace stays advisor at BridgeBio Oncology (BBOT) - Stock Titan
[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
BridgeBio Oncology Therapeutics appoints new CEO and COO - MSN
Latest BBOT NewsBBOT Presents Preclinical Data Demonstratin... - Stock Titan
BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset - MSN
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy - Investing.com
Stifel Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
BridgeBio (BBOT) Stock: Price Pattern Formation | Q4 2025: EPS Beats ForecastsDividend Growth Rate - Xã Thanh Hà
BridgeBio Oncology Overhauls Leadership for Next Development Phase - TipRanks
BridgeBio Oncology names Pedro Beltran as new CEO By Investing.com - Investing.com India
BridgeBio Oncology Therapeutics (BBOT) registers 63.1M shares; Beltran named CEO - Stock Titan
New leadership team takes shape at BridgeBio Oncology (Nasdaq: BBOT) - Stock Titan
BBOT Presents Preclinical Data Demonstrating pan-KRAS - GlobeNewswire
BridgeBio Oncology names Pedro Beltran as new CEO - Investing.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - marketscreener.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as - GlobeNewswire
BridgeBio Oncology presents preclinical data on BBO-10203 By Investing.com - Investing.com South Africa
BridgeBio Oncology presents preclinical data on BBO-10203 - Investing.com
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker - GlobeNewswire
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT) - Seeking Alpha
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - Yahoo Finance
Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT - Moomoo
BridgeBio Reports FDA Fast Track Label for BBO-11818 - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
BridgeBio Oncology Therapeutics stock jumps 10% on FDA nod By Investing.com - Investing.com Nigeria
BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment - marketscreener.com
FDA grants fast track status to BridgeBio’s pancreatic cancer drug By Investing.com - Investing.com Canada
BridgeBio Oncology Therapeutics, Inc recently revealed that the eagerly awaited updated data from its Phase I clinical trial is expected to be released in the second half of 2026. - Bitget
BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administr - Bitget
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 - GlobeNewswire
Bridgebio Oncology Therapeutics Inc (BBOT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):